To test its propensity for treatment of AD pathology in vivo, eight-month-old APP/PS1 mice were subjected to daily gavage treatments with 100 mg/kg NB-02 dose or vehicle cocktail (Fig. 1A). Here, APP is linked to Alzheimer disease.